Duration of anticoagulation treatment in patients with venous thromboembolism.
Deep vein thrombosis and pulmonary embolism are clinical manifestations of venous thromboembolism, and they necessitate anticoagulant therapy in most cases. The duration of treatment is predicated on a balance between the risk of recurrent disease and the risk of bleeding inherent to anticoagulant therapy. It is important that physicians are aware of evidence-based guidelines that can enhance decision-making discussions with patients about the risks and benefits of the different durations of treatment. Keeping patients well informed as they consider these difficult choices helps them assume responsibility and may improve compliance in accordance with the tenets of osteopathic principles of care.
Henry Ford Hospital K-15, 2799 W Grand Blvd, Detroit, MI 48202-2608, USA. skaatz1@hfhs.org
Scott
S
Kaatz
Waqas
W
Qureshi
Christopher
C
Fain
David
D
Paje
D000925:Anticoagulants / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications; D011655:Pulmonary Embolism / Q000188:drug therapy; D012008:Recurrence; D018570:Risk Assessment; D055502:Secondary Prevention; D013924:Thrombophlebitis / Q000150:complications; D013997:Time Factors; D054556:Venous Thromboembolism / Q000188:drug therapy*; D020246:Venous Thrombosis / Q000188:drug therapy / Q000209:etiology
D000925:Anticoagulants